<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539145</url>
  </required_header>
  <id_info>
    <org_study_id>RO-012020</org_study_id>
    <nct_id>NCT04539145</nct_id>
  </id_info>
  <brief_title>CHOCO-CABANA Trial</brief_title>
  <official_title>Chocolate PTA Balloon Compared to Conventional Balloon Angioplasty for Sustained Lumen Gain in Below the Knee Arteries - CHOCO-CABANA Trial-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Rosenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herz-Zentrums Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Karlsbad-Langensteinbach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elblandklinikum Radebeul Interdisziplinäres Gefäßzentrum Radebeul / Riesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LKH-Universitätsklinikum Graz Univ. Klinik für Innere Medizin Klin. Abteilung für Angiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanusch-Krankenhaus Kardiovaskuläres Zentrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SCO:SSiS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>coreLab Black Forest GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Rosenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed 120 patients at about 6 to 8 study centers. Only patients with&#xD;
      clinical conditions requiring assessment of patency of the treated BTK lesions at 6 months&#xD;
      post procedure by MRA as part of standard care to prevent amputations as consequence of&#xD;
      non-detected re-stenosis/occlusions will be included in the study. The sequence in which the&#xD;
      individual patients will be treated will be randomized with the Chocolate PTA balloon and the&#xD;
      uncoated conventional PTA balloon at each center. 60 patients will be randomized to uncoated&#xD;
      conventional PTA balloon treatment and 60 patients to treatment with the Chocolate PTA&#xD;
      balloon.&#xD;
&#xD;
      All lesions in each patient (lesions that fulfill the inclusion/exclusion criteria) should be&#xD;
      treated as the patient is randomized.&#xD;
&#xD;
      In patients with long lesions more than one balloon may be used. Overlapping of balloons (at&#xD;
      least 10mm) is mandatory to avoid untreated gaps between sequential treatments. Follow up&#xD;
      will be performed at 1 and 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">March 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>120 patients (60 per group) Special balloon (chocolate balloon with a special nitiol cage around the balloon - not drug coated) versus standard uncoated balloon</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Randomization per envelope</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recoil (lumen loss &gt; 30%) 15-30 min after study intervention angiographically documented and analyzed by a core-lab</measure>
    <time_frame>15-30 min after study intervention</time_frame>
    <description>The minimal lumen of the artery in the area of Intervention in mm will be compared directly after the Intervention and at 15-30 minuntes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the loss of patency greater than 50% in the MRA after six month</measure>
    <time_frame>6 month</time_frame>
    <description>the lumen of the artery directly after the Intervention, 15 min after the Intervention and at 6 months will be compared (in mm). It is a secondary outcome if the loss is greater than 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the re-occlusion rate at 6 months (measured by MRA)</measure>
    <time_frame>6 month</time_frame>
    <description>lumen = 0 mm = recocclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual stenosis (MLD post compared to RVD, % of RVD) &gt;50% after the invention</measure>
    <time_frame>immedetely after the intervention</time_frame>
    <description>interventional success: lumen of the artery directly after the Intervention (compared to the healthy vessel next to the lesion - in mm) - RVD = reference vessel Diameter, MLD = Minimum lumen diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound status at 1 and 6 months:</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>as estimated by the patient (healed, improved, no change, worsened)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization TLR rate at 1 and 6 months</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>if an endovascular of surgical therapy of the lesion which was treated is performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 1 and 6 months</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical presentation (Rutherford 0, 1, 2, 3, 4, 5 or 6 at 30 days and 6 months</measure>
    <time_frame>1 and 6 month</time_frame>
    <description>Rutherford 0 = no symptoms, Rutherford 6 = worst symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancle brachial index (ABI) compared to baseline and post intervention and 6 months</measure>
    <time_frame>directly after the intervention and 6 month</time_frame>
    <description>Blood pressure in the arm divided by blood pressure in the distal leg (normal value: 0.8-1.2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DUS vs. MRA at 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>both by DUS and MRA % Stenosis of the index lesion will be calculated. They will be compared in order to see if DUS has the same value as MRA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Chocolate PTA balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>POBA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention with regular baloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chocolate PTA Balloon</intervention_name>
    <description>Chocolate PTA Balloon</description>
    <arm_group_label>Chocolate PTA balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional balloon angioplasty</intervention_name>
    <description>conventional bal-loon angioplasty</description>
    <arm_group_label>POBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 years of age&#xD;
&#xD;
          2. Chronic stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries&#xD;
&#xD;
          3. Patients with clinical conditions requiring assessment of vessel patency of treated&#xD;
             BTK lesion 6 months post procedure as part of clinical standard of care to prevent&#xD;
             amputa-tions as consequence of non-detected re-stenosis&#xD;
&#xD;
          4. BTK intervention with lesions between 1 and 25 cm&#xD;
&#xD;
          5. Sufficient outflow of the treated artery to the foot (less than 50% stenosis or&#xD;
             sufficient collaterals)&#xD;
&#xD;
          6. All BTK lesions either to be treated with conventional PTA or with the Chocolate PTA&#xD;
             balloon (if inclusion criteria 4 and 5 apply)*&#xD;
&#xD;
             * The longest lesion will be taken as primary lesion. All other lesions will be also&#xD;
             analyzed within the study protocol but separately evaluated. If a secondary lesion&#xD;
             does not fulfill the inclusion criteria 4 and 5, the lesion can be treated upon the&#xD;
             decision of the operator and will not be analyzed within the study protocol.&#xD;
&#xD;
          7. Rutherford 3-5 patients&#xD;
&#xD;
          8. Patients who are able to be followed to assess vessel patency according to standard&#xD;
             lo-cal hospital care (e.g. DUS, MRA)&#xD;
&#xD;
          9. Successfully treated inflow lesions up to TASC B&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute or sub-acute thrombosis&#xD;
&#xD;
          2. In-stent restenosis&#xD;
&#xD;
          3. Rutherford 1-2 and 6&#xD;
&#xD;
          4. Patient who is not fit for follow-up (including contraindication for MRA)&#xD;
&#xD;
          5. Vessel preparation with cutting balloon, lithotripsie, atherectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus Kardiovaskuläres Zentrum</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach GmbH</name>
      <address>
        <city>Karlsbad (Baden)</city>
        <state>Baden-Wuettenberg</state>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>BW</state>
        <zip>73000</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tepe</name>
      <address>
        <city>Rosenheim</city>
        <state>BW</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <state>BW</state>
        <zip>73022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Radebeul Interdisziplinäres Gefäßzentrum Radebeul / Riesa</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Rosenheim</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Gunnar Tepe</investigator_full_name>
    <investigator_title>Chief Physician of the Radiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

